QQQ4.80%

Trending

ADA5.23%

home Symbol DMACnews

DMACDiaMedica Therapeutics Inc

$5.64

$0.20

(3.42%)

Today

Closed $5.64

$0.00

(0.00%)

After Hours

Updated: 04:15 PM EDT

EarningsAug 11

Mkt Cap$314.68M

Vol195,882.00

Fundamentals

Mkt Cap

$314.68M

Volume

52W High

$10.42

52W Low

$3.48

PE Ratio

-8.00

Avg. Volume

170,675.45

EPS (Annual)

-$0.6974

Rev/Employee

$0.00

Earnings

Aug 11

Info

News

all

press releases

DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held...

Business Wire

More News

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, today announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in...

Business Wire

DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...

Business Wire

DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic...

Business Wire

DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-diamedica-therapeutics-inc-stock...

MarketBeat

DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...

Business Wire

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the company, MarketBeat.com reports. One...

MarketBeat

DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference

DiaMedica Therapeutics (NASDAQ:DMAC) President and CEO Rick Pauls outlined the company's development programs for its lead candidate, DM199, during a presentation at the RedChip Biotech Investor...

MarketBeat

Q1 EPS Estimate for DiaMedica Therapeutics Raised by Analyst

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for DiaMedica Therapeutics in a report released on Wednesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($0.17) per...

MarketBeat

HC Wainwright Issues Pessimistic Estimate for DMAC Earnings

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Free Report) - Research analysts at HC Wainwright reduced their FY2029 EPS estimates for DiaMedica Therapeutics in a research note issued to investors on Wednesday, April 1st. HC Wainwright analyst M. Caufield now expects that the company will post earning...

MarketBeat

...

Advertisement|Remove ads.